Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials

M. J. Davies, L. J. Aronne, I. D. Caterson, A. B. Thomsen, P. B. Jacobsen, S. P. Marso

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person-years) compared to 10 participants in the comparators group (3.65 events/1000 person-years). The hazard ratio for liraglutide 3.0mg compared to comparators was 0.42 (95% confidence interval, 0.17-1.08). In this analysis, liraglutide 3.0mg treatment was not associated with excess cardiovascular risk. However, the wide confidence intervals and retrospective adjudication of events in two of the trials are limitations of the analysis.

Original languageEnglish (US)
JournalDiabetes, Obesity and Metabolism
DOIs
StateAccepted/In press - 2017

Fingerprint

Randomized Controlled Trials
Obesity
Placebos
Confidence Intervals
Controlled Clinical Trials
Proportional Hazards Models
Liraglutide
Stroke
Myocardial Infarction
Safety
Weights and Measures
Therapeutics

Keywords

  • Antiobesity drug
  • Cardiovascular disease
  • Clinical trial
  • GLP-1
  • GLP-1 analogue
  • Liraglutide

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Liraglutide and cardiovascular outcomes in adults with overweight or obesity : A post hoc analysis from SCALE randomized controlled trials. / Davies, M. J.; Aronne, L. J.; Caterson, I. D.; Thomsen, A. B.; Jacobsen, P. B.; Marso, S. P.

In: Diabetes, Obesity and Metabolism, 2017.

Research output: Contribution to journalArticle

@article{15be9efec308490f982b2855853aead0,
title = "Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials",
abstract = "The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person-years) compared to 10 participants in the comparators group (3.65 events/1000 person-years). The hazard ratio for liraglutide 3.0mg compared to comparators was 0.42 (95{\%} confidence interval, 0.17-1.08). In this analysis, liraglutide 3.0mg treatment was not associated with excess cardiovascular risk. However, the wide confidence intervals and retrospective adjudication of events in two of the trials are limitations of the analysis.",
keywords = "Antiobesity drug, Cardiovascular disease, Clinical trial, GLP-1, GLP-1 analogue, Liraglutide",
author = "Davies, {M. J.} and Aronne, {L. J.} and Caterson, {I. D.} and Thomsen, {A. B.} and Jacobsen, {P. B.} and Marso, {S. P.}",
year = "2017",
doi = "10.1111/dom.13125",
language = "English (US)",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Liraglutide and cardiovascular outcomes in adults with overweight or obesity

T2 - A post hoc analysis from SCALE randomized controlled trials

AU - Davies, M. J.

AU - Aronne, L. J.

AU - Caterson, I. D.

AU - Thomsen, A. B.

AU - Jacobsen, P. B.

AU - Marso, S. P.

PY - 2017

Y1 - 2017

N2 - The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person-years) compared to 10 participants in the comparators group (3.65 events/1000 person-years). The hazard ratio for liraglutide 3.0mg compared to comparators was 0.42 (95% confidence interval, 0.17-1.08). In this analysis, liraglutide 3.0mg treatment was not associated with excess cardiovascular risk. However, the wide confidence intervals and retrospective adjudication of events in two of the trials are limitations of the analysis.

AB - The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial. With liraglutide 3.0mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person-years) compared to 10 participants in the comparators group (3.65 events/1000 person-years). The hazard ratio for liraglutide 3.0mg compared to comparators was 0.42 (95% confidence interval, 0.17-1.08). In this analysis, liraglutide 3.0mg treatment was not associated with excess cardiovascular risk. However, the wide confidence intervals and retrospective adjudication of events in two of the trials are limitations of the analysis.

KW - Antiobesity drug

KW - Cardiovascular disease

KW - Clinical trial

KW - GLP-1

KW - GLP-1 analogue

KW - Liraglutide

UR - http://www.scopus.com/inward/record.url?scp=85032819771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032819771&partnerID=8YFLogxK

U2 - 10.1111/dom.13125

DO - 10.1111/dom.13125

M3 - Article

C2 - 28950422

AN - SCOPUS:85032819771

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

ER -